Welcome to the Oncomine Blog
Evaluating NGS technologies for in-house comprehensive genomic profiling
11/13/2024 |
Research
In everyday practice, it is common for pathology labs to evaluate >50% cytological specimens across solid tumors especially in lung and pancreatic...
-
Evaluating NGS technologies for in-house comprehensive genomic profiling
In everyday practice, it is common for pathology labs to evaluate >50% cytological specimens acro... -
Advancements in Liquid Biopsy NGS for Precision Oncology
How can we enhance the clinical utility and accessibility of liquid biopsy NGS? Liquid biopsy next-g... -
Revolutionizing Cancer Treatment Selection with Next-Generation Sequencing
Introduction In a recent interview with the Anatomical and Molecular Pathology Lab at Sydpath, St. V... -
Performing an analytical validation for a next-generation sequencing workflow: A Q&A session with Liverpool Clinical Laboratories
Recently, Thermo Fisher Scientific sat down with Carolina Felix, Senior Biomedical Scientist at the ... -
When a rare cancer lab experienced unexpected NGS results, a Thermo Fisher Scientific TAS solved the puzzle
Some NGS runs on Dr. Gabriella Gamberi’s Ion GeneStudio S5 System had a high number of low-quality r... -
Announcing the Latest Oncomine Clinical Research Grant Awardees Advancing Precision Medicine in Oncology
Thermo Fisher Scientific has announced the recipients of the latest Oncomine Clinical Research Grant... -
Recommendations for Equitable and Widespread Implementation of Liquid Biopsy in Cancer Care
A recently published article by the BLOODPAC Consortium details the potential of liquid biopsy in th... -
Development of a Novel Metric to Measure Genomic Instability - 35th European Congress of Pathology Poster
The theme of the 35th European Congress of Pathology (ECP) “Pathology – a bridge between science and... -
Q&A with Integra Connect: When Waiting to Treat Leads to Better Outcomes
Precision medicine is on the rise. However, these groundbreaking, targeted therapies for hard-to-tre...